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Abstract
The products of the collagen-al (I) and -a2(I) genes form the
triple helical molecule collagen type I, which constitutes the
major ECM protein in tissue fibrosis. The collagen-al (I) gene
is mainly transcriptionally regulated, and its promoter activity
depends on the interaction ofthe transcription factors NF-I and
Spi with a tandem repeat of evolutionary conserved NF-I/Spl
switch elements. An increased affinity of Spl to these elements
has been observed in experimental liver fibrosis. Here, we dem-
onstrate that the DNA binding drug mithramycin displays a
high affinity binding to the GC-rich elements in the collagen-
al (I) promoter as measured by DNAse I protection and gel
retardation assays.
Mithramycin interferes with Spl but not with NF-I binding
to these sites. At a concentration of 100 nM, mithramycin effi-
ciently reduces basal and TGF- -stimulated al (I) gene ex-
pression in human primary fibroblasts. The transcriptional ac-
tivity and mRNA steady state levels of other genes, including
the collagenase gene, as well as the growth rate of fibroblasts
remained unchanged on exposure to this drug. Taken together,
our results indicate that the transcriptional activity ofthe type I
collagen gene highly depends on its GC-rich regulatory ele-
ments, and further, that these elements can be differentially
blocked, thereby changing the balance between ECM struc-
tural and degrading gene activities in human fibroblasts. (J.
Clin. Invest. 1993. 92:2916-2921.) Key words: mithramycin.
collagen al (I) - regulation * gene expression - Spl
Introduction
The synthesis and deposition ofECM proteins is highly regu-
lated and plays a critical role in tissue development, homeosta-
sis, wound healing, and inflammation ( 1-3). Overexpression
ofECM proteins may lead to tissue fibrosis with severe impair-
ment of organ function. A hallmark of fibrotic diseases such as
pulmonary fibrosis, hepatic cirrhosis, progressive systemic scle-
rosis, and osteomyelofibrosis, is the pathological accumulation
of the ECM proteins collagen type I and fibronectin (4-7).
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Type I procollagen mRNA levels are increased in experimental
and clinical fibrotic states (6, 8, 9), which implies a regulation
at the pretranslational level. Colocalization of members of the
TGF-(3 family of growth and differentiation factors with ECM
proteins in affected tissues (3, 8) and the stimulatory effect of
TGF-3 on collagen and fibronectin steady state mRNA levels
(3, 10) suggest an important role of these growth factors in
tissue fibrosis. Collagen type I is a triple helical molecule com-
posed oftwo al (I) and one a2(I) collagen gene products. Re-
cent progress has lead to the identification ofimportant regula-
tory elements of the murine and human a 1(I) gene. Several
binding sites for the GC box binding transcription factor Spl
were located in the first intron of the human gene (11), to
which enhancer-like activities were ascribed ( 12). In addition,
two highly conserved GC box elements were functionally char-
acterized in the promoter of the murine al (I) gene ( 13). Both
elements also contain an overlapping CCAAT box motif and
function individually as mutually exclusive binding sites for
the transcription factors NF-I (CCAAT box factor) and Spl
(GC box factor) thereby creating a direct repeat of NF-I/Spl
switch elements ( 14). The two elements control the high basal
activity of the murine a I(I) gene in fibroblasts ( 15), which
contain both high NF-I and Spl binding activity. In contrast,
only very low amounts ofSpl binding activities can be detected
in a normal liver where only minimal amounts of a 1(I) tran-
scripts can be measured. Interestingly, this weak binding affin-
ity of Spl to the a I(I) promoter was substantially increased
and correlated with induced al (I) mRNA levels in different
models of experimental liver fibrosis ( 16).
Under the assumption that GC-rich elements play a crucial
role in determining the transcriptional activity of the human
a I (I) gene, we have examined the effect of the GC-binding
antibiotic mithramycin (16, 18-20) on collagen gene regula-
tion in human primary fibroblasts. Our results reveal that
mithramycin inhibits Spl but not NF-I binding to the NF-I/
Spl switch elements in vitro.
At nontoxic doses, mithramycin selectively decreases basal
a I(I) collagen gene transcription and inhibits TGF-13I induc-
tion ofa I (I) mRNA levels in human primary fibroblasts. This
indicates that although the activity ofthe collagen-al (I) gene is
highly dependent on GC-rich regulatory elements, the activity
of other genes, including the collagenase gene, is not.
Methods
Materials. Mithramycin was obtained from Sigma Chemical Co. (St.
Louis, MO) as a powder that was resuspended in sterile water and was
further diluted in culture medium before use. PMA (Sigma Chemical
Co.) was dissolved in 100% ethanol and diluted in culture medium to a
final concentration of 100 nM. Lyophilized human TGF-,61 was ob-
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tained from GIBCO BRL (Gaithersburg, MD) and was prepared as
recommended by the manufacturer. All radiochemicals were obtained
from Amersham International (Amersham, United Kingdom).
Cell culture. Primary human embryonic lung fibroblasts (strain
FH109) were maintained at subconfluency in RPMI medium supple-
mented with 10% fetal calf serum and antibiotics in a 5% CO2 atmo-
sphere in air. For the toxicity testing cells were plated out at low density
on 35-mm tissue culture plates (Falcon Plastics, Cockeysville, MD) for
24 h. Next, media was replaced by fresh supplemented media contain-
ing either no or the indicated concentrations ofmithramycin. Cell num-
bers were counted after trypsinization and trypan blue dye exclusion
immediately, and 1, 5, and 8 d after addition ofmithramycin. Average
numbers of three independent experiments were calculated.
Isolation andfractionation ofRNA. FH 109 cells were scraped off
the culture plates and washed twice in PBS. RNA was extracted and
purified according to the protocol by Huang and High (21). Total
RNA (10 gg/lane) was fractionated on 1% agarose gels containing
formaldehyde and transferred to nylon membrane filters (Schleicher &
Schuell, Dassel, Germany) by standard techniques. Probe preparation
and hybridization was carried out as described (22).
Nuclear run-on assay. For nuclear run on transcription assays, sub-
confluent FH109 cells (108 cells/experiment) were treated with the
indicated concentrations of mithramycin for 3 h, scraped offthe plates,
washed several times in ice-cold PBS, and lysed by vortexing in 10 ml
RSB (10mM Tris-HCl, pH 7.5, 5 mM KCl, and 3 mM MgCl) contain-
ing0.5% Nonidet-P40 on ice for 5 min. Nuclei were collected by centrif-
ugation at 500 gat 40C for 5 min and washed once in TNM buffer (100
mM Tris-HCl, pH 7.5, 10mM NaCl, and 3 mM MgCl). After centrifu-
gation at 500 g at 4°C for 5 min. nuclei were resuspended in 500,41 1x
reaction buffer (3x stock contains 60 mM Tris, pH 8.0, 30 mM MgCl,
3 mM MnCl, 420mM KCl, 42 mM f,-mercaptoethanol, and 60% glyc-
erol), transferred to an Eppendorf tube, and spun again at 3,000 rpm/
min at 4°C for 5 min to finally reduce the reaction volume to 150 ,l.
The nuclear run reaction was started by adding 125 qI reaction mix
(250 ,ul 3x reaction buffer, 15 gl 100 mM ATP, 7.5 ,l 100 mM GTP
and CTP, 5 IA RNasin, and 340 jd DEPC H20) and 25 Al [a 32P]UTP
(10 MCi/Ml, 3,000 Ci/mmol) to the nuclei. After incubating the reac-
tion at 26°C for 10 min, 1.5,ul of 0.2 M CaCl and 2.4 Al ofRNAse free
DNAse I (10 ,g/rxn) was added and incubated at 37°C for 15 min.
The nuclear RNA was extracted by following the protocol of Huang
and High (21). Generally 4-8 X I07' cpm radiolabeled RNA/reaction
were extracted and hybridized to filter bound cDNA fragments (1,g/
slot) as described (22). After hybridization at 42°C for 72 h, filters
were washed, air dried and exposed at -70°C to a X-O-Mat film (East-
man Kodak, Rochester, NY) with an intensifying screen (22). Autora-
diograms were quantitated by a scanning laser densitometer interfaced
with an integrater.
cDNA andpromoter probes. The plasmid pHF677 (23) containing
cDNA for the human a I (I) collagen and the plasmid pWS-2.5 /CAT
(24) containing the human al (I) collagen promoter were kindly pro-
vided by Dr. F. Ramirez (Brookdale Center for Molecular Biology,
Brookdale, NY). The plasmid pWS-2.5/CAT was restricted with
PvuII (-252 bp) and BamHI (+123 bp) and the isolated promoter
fragment was subcloned into pUCl9 restricted with BamHI and SmaI
yielding pUCl9-al(I). The plasmid pCIIase (25) containing the
cDNA for human fibroblast collagenase was kindly provided by Dr. P.
Herrlich (Kernforschungszentrum Karlsruhe, Karlsruhe, Germany).
The plasmid pDT 151-7 (26) for the human collagen-al (III) cDNA
was a gift of Dr. B. de Crombrugghe (M. D. Anderson Hospital and
Tumor Institute, Houston, TX). The plasmid pHcGAP for human
glyceraldehyde-3-phosphate dehydrogenase was purchased from Amer-
ican Type Culture Collection (Rockville, MD). The cDNA encoding
c-jun was kindly provided by M. Karin (University of California, San
Diego, CA) (27), and the cDNA of rat fibronectin was provided by
R. 0. Hynes (Massachusetts Institute of Technology, Cambridge,
MA) (28).
Nuclear protein extraction. Nuclear proteins were extracted from
cultured F 109 embryonic lung fibroblasts as previously described (15).
DNAse Iprotection assay. The plasmid pUCI9-al (I) was digested
with EcoRI (multiple cloning site 5' of basepair position -252) and
SmaI (-17 bp) and the resulting fragment containing the al (I) pro-
moter was gel purified and endlabeled by a fill in reaction at the EcoRI
site with Klenow fragment of DNA polymerase I (Boehringer Mann-
heim GmbH, Mannheim, Germany) using [a 32P]dATP (3,000 Ci/
mmol). Either nuclear FH109 protein extracts, BSA, or mithramycin
were incubated with 30 kcpm/reaction of probe for 20 min on ice.
DNAse I protection assays were further carried out essentially as de-
scribed ( 15).
Gel retardation assay. The FP2 oligonucleotide spanning the pro-
moter sequences from -131 to -1 10 bp ( 15 ) was endlabeled with T4
kinase (Boehringer Mannheim GmbH) using [a32P]ATP (3,000 Ci/
mmol). The probe (20 kcpm/ reaction) was either incubated alone or
with 20 ,gg nuclear FH 109 protein extracts containing no or increasing
concentrations of mithramycin ranging from 10 nM to 100 ,gM. The
standard binding reaction was carried out at 20°C for 20 min as de-
scribed previously (29).
Results
Collagen (I) and collagenase mRNA levels. Human FH109
primary fibroblast cells were exposed to the antibiotic mithra-
mycin. As measures of toxicity, we assessed cell growth, mor-
phology and viability ofFH 109 cells cultured in the presence of
different concentrations of mithramycin over a period of 8 d.
At concentrations of mithramycin ranging from 10 nM to 100
nM, cell growth and morphology were not altered as compared
to untreated controls. A fivefold reduction in cell growth was
observed when a mithramycin concentration of 1 ,uM was
used, while cell morphology remained unchanged (data not
shown). However, concentrations as high as 10 AM resulted in
complete cell death after 4 d (Fig. 1).
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Figure 1. Toxicity testing of mithramycin on cultured primary human
FH 109 fibroblast cells. FH109 cells were cultured as described in
Methods. After 24 h, the medium was changed containing either no
(control) or the indicated concentrations of mithramycin. Cell mor-
phology was examined daily by light microscopy. At the indicated
time points, the FH 109 cells were trypsinized, and viable cells were
counted after trypan blue exclusion. The experiments were carried
out in triplicate and the average numbers are shown. - * , Con-
trol; - -, lOnM;-o -, lOOnM; - -, I M; *-, 10
1AM.
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from control and mithramycin-treated FH 109 cells after 24
and 48 h for Northern blot analysis. The results after hybridiza-
tion with a human collagen-a 1(I) and the human collagenase
cDNA are shown in Fig. 2. Hybridization with the human
a 1(I) collagen gene probe revealed two transcripts of 4.7 and
5.7 kb in size, which result from the different usage of two
polyadenylation signals 1 kb apart (30). After 24 h, the
a I(I) 4.7-kb transcript declined severalfold at all concentra-
tions ofmithramycin ranging from 10 nM to 10 ,M (Fig. 2). A
further decrease ofa 1(I) transcripts was observed after 48 h of
incubation. In contrast, the steady state collagenase mRNA
levels were reduced only at the toxic concentration of 10 'M
but remained unaffected at concentrations ranging from 10
nMto 1 AM(Fig. 2).
Protein kinase C (PKC) activation and mithramycin. PKC
activation by phorbol esters like PMA reduces steady state col-
lagen-a 1(I) mRNA levels (31) and stimulates collagenase
transcription (32) in human fibroblasts. To study the interac-
tion of mithramycin and PMA with respect to collagen-a I (I)
mRNA expression, FH 109 cells were incubated with both
drugs for 1, 3, 6, and 24 h (Fig. 3). A concentration of 100 nM
PMA (P) reduced a I(I)mRNA levels after 1 h with a maximal
effect after 6 h when compared to controls (medium treatment
only), while incubation of FH 109 cells with mithramycin
downregulated a 1(I) mRNA levels after 3 h with still decreas-
ing levels after 24 h, suggesting different kinetics of regulation.
When both drugs were combined, the a 1 (I) transcript became
even more reduced than with either drug alone, suggesting an
additive effect that was best demonstrated after 24 h of treat-
ment. Interestingly, while the strong increase of collagenase
mRNA levels by PMA after 3, 6, and 24 h were reduced by the
coincubation with mithramycin, mithramycin treatment alone
had no significant effect on steady state collagenase levels indi-
cating that mithramycin directly or indirectly interferes with
the enhanced collagenase induction by PMA.
The induction of the collagenase gene by PMA is mediated
through an APl binding site in the collagenase promoter (re-
viewed in reference 33). We tested steady state mRNA levels of
the proto-oncogene c-jun as one member of the AP1 complex





















Figure 2. Northern blot analysis of total RNA (10 jig per lane) from
mithramycin-treated FH 109 fibroblasts. Cells were incubated for the
indicated time (24 and 48 h) in medium containing either no
mithramycin or mithramycin at a final concentrations of 10 gM, 1
IAM, 100 nM, and 10 nM. The blot was sequentially probed with ra-
diolabeled human collagen-a (I), collagenase, and GAPDH cDNAs.
Shown are densitometric plots after normalization of collagen-a 1(I)
and collagenase signals for GADPH. Signal intensities from unstimu-
lated cells were arbitrarily set 100%. -o-- , 24 h; ..*--O- , 48 h.
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Figure 3. Northern blot analysis of total RNA from mithramycin and
PMA-treated FH 109 fibroblasts. Cells were cultured at 70-80% con-
fluency for the indicated time ( 1, 3, 6, and 24 h) in control medium
or in medium containing either a 10 nM concentration of mithramy-
cin, a 100 nM concentration ofPMA, or both drugs combined. The
same filter was probed, stripped, and reprobed with the indicated ra-
diolabeled cDNAs including a GAPDH cDNA. Shown are densito-
metric plots after normalization of fibronectin, collagen-a 1 (I), c-jun,
and collagenase signals for GADPH. Signal intensities from unstimu-
lated and uncultured cells were arbitrarily set 100%. a, Medium; o,
mithramycin; m, PMA; a, mithramycin/PMA.
basal and early PMA-induced c-jun mRNA levels were unaf-
fected after 1 and 3 h of coincubation with mithramycin, but
decreased below their respective control levels 6 and 24 h after
mithramycin treatment. These data suggest that inhibition of
the collagenase induction might be associated with a reduction
of c-jun transcripts.
Preincubation ofFH 109 cells with a 100 nM concentration
of mithramycin for 24 h resulted in a complete inhibition of
PMA-induced transcription ofthe collagenase gene after 1 and
8 h of treatment (Fig. 4) when compared to the corresponding
controls. In this experiment, it was also shown that incubation
with human TGF-#1 at a 100 pM final concentration lead to a
slight increase ofa 1(I) mRNA levels after 8 h in the absence of
mithramycin, while a 24-h preincubation with mithramycin
almost completely abolished this induction.
The mRNA levels of another important ECM protein in
tissue fibrosis, fibronectin, were also tested (Fig. 3). While
PMA alone shows a weak stimulatory effect after 24 h over
control level, mithramycin decreased both basal and PMA-in-
duced fibronectin mRNA levels (Fig. 3, lanes 13 and 15, respec-
tively). Mithramycin had, however, no significant effect on the
mRNA levels of the GAPDH housekeeping gene.
Mithramycin interferes with transcription factor binding.
The first 500-bp upstream of the start site of transcription of
the human a 1(I) collagen gene is highly GC-rich (> 60%), as
compared to the human collagenase promoter (GC-bp content
= 45%). Since mithramycin has a high affinity to GC-rich
stretches ofDNA, we determined mithramycin binding sites in
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Figure 4. Northern blot analysis of total RNA from FH109 cells pre-
treated with mithramycin. FH 109 fibroblasts were cultured in me-
dium containing either no or a 100 nM concentration of mithramycin
for 24 h. Cells were then cultured in media supplemented with 1%
fetal calf serum in the presence ofhuman TGF-lI at a 5 pM or PMA
at a 100 nM final concentration for the indicated time period. The
blot was hybridized with the human collagen-a l (I), collagenase, and
GAPDH cDNA radiolabeled probes. Shown are densitometric plots
after normalization of collagen-a 1(I) and collagenase signals for
GADPH. Signal intensities from unstimulated and uncultured cells
were arbitrarily set 100%. m, PMA; o, TGF.
the human a I(I) promoter by DNAse I protection assays,
alongside the footprints mediated by nuclear proteins from un-
treated FH109 cells (Fig. 5). This assay reveals a concentra-
tion-dependent binding of mithramycin (Fig. 5, lanes 2-4) to
all GC-rich regions of the a I (I) promoter that are also pro-
tected from DNAse I digest by the nuclear fibroblast extracts
(Fig. 5, lanes 5 and 6, and schematic drawing). This result
suggested the possibility that mithramycin might interfere with
transcription factor binding to the collagen-a 1(I) promoter.
Additional information on this possible interference of
mithramycin with transcription factor binding was sought in
gel retardation assays (Fig. 6). For this purpose, the FP2 (foot-
print 2) oligonucleotide, which contains an complete NF-I/
Sp I switch element and spans from basepairs - 130 to -110 of
the a1(I) promoter, was prepared as a radiolabeled probe.
While no FP2-probe was retarded in the absence of nuclear
extract (Fig. 6, lane I), both Sp I and NF-I transcription factor
binding activities were present in the FH 109 protein extracts.
The identity of both factors was tested in competition experi-
ments using oligonucleotides with high affinity consensus bind-
ing sites for either factor ([15 ], and data not shown). Addition-
ally, the nuclear extracts were coincubated with mithramycin
ranging from 10 nM to 10 ,qM final concentration (Fig. 6, lanes
3-7, respectively). At 10 tiM, mithramycin competed with the
binding of Spl and increased NF-I binding to the FP2 probe
(Fig. 6, lane 7).
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Figure 5. DNAse I protection of the human collagen-al (I) promoter
mediated by mithramycin or nuclear FH 109 proteins. A DNA frag-
ment containing the collagen-al (I) promoter region (-252--17 bp)
was radiolabeled at the -252 end. The G-specific Maxam and Gilbert
sequencing reaction of the a I (I) promoter is shown in lane 1. The
probe was incubated with binding buffer containing no or the indi-
cated molar concentrations of mithramycin. The protection pattern
with the two indicated amounts in milligrams of FH 109 nuclear pro-
tein extracts is shown beside the control reaction containing 30 jig
BSA. A schematic footprinting pattern of the DNAse I protections
mediated by the nuclear extracts is also shown.
Mithramycin inhibits a l (I) collagen gene transcription. To
determine the potential role of mithramycin on a1(I) gene
activity, its rate of transcription was directly analyzed by nu-
clear run on transcription assays. Nuclei from controls and


















to the NF-If/Sp I switch
element. In a gel retar-
dation assay, a FP2 oli-
gonucleotide spanning
|Spi the -13I--llO seg-
ment of the collagen-
al (I) promoter was ra-
diolabeled and incu-
NF-1 bated with no additions
(lane I) or 20 ,g of nu-
clear FH 109 fibroblast
protein extract (lanes
2-7). The binding reac-
tion contained either
no (lanes and 2) or
increasing concentra-
tion of mithramycin
ranging from 10-8 to
*i l0-4 M (lanes 3-7, re-
free spectively). The binding
probe activities ofthe retarded
bands and the free
7 probe are shown.
FH 109 cells that were incubated with mithramycin at 1 nM,
100 nM, and 10 ,uM final concentrations were harvested after 3
h. Radiolabeled run on transcripts were prepared and hybrid-
ized to filter-bound cDNA probes. Fig. 7 summarizes the indi-
vidual transcription rates that were calculated as the transcrip-
tional activity relative to the controls, which were set as 100%.
A final concentration of 1 nM, mithramycin had no effect on
the activity ofthe different genes tested. At 100 nM, mithramy-
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Figure 7. Mithramycin differentially interferes with intracellular gene
transcription. In a nuclear run-on transcription assay, nuclei from
cultured FH 109 cells were isolated after treatment with no or the in-
dicated concentrations of mithramycin for 3 h. The mRNA tran-
scription, was allowed to complete in the presence of a [32P] UTP and
the labeled transcript was extracted and hybridized to filter bound
cDNA probes as described in Methods. Autoradiograms were laser
scanned and the transcription rates calculated as the relative gene
transcription of the respective control cDNAs (= 00%). o, 1 nM; c,
100 nM;., lIOAM.
al (I) gene activity by 60%. In contrast, the transcription ofthe
collagenase, a1(111) collagen, and GAPDH genes remained
unaltered. Only at 10 gM were all genes affected, which again
indicates a toxic effect of mithramycin at this concentration
(see Fig. 1).
Discussion
The promoter of the a I(I) collagen gene is highly active in
collagen-producing fibroblasts ( 13) and mainly regulated by
the interaction ofthe transcription factors NF-I and Sp I with a
tandem repeat of NF-I/Sp switch elements ( 14, 15 ). Overex-
pression of Sp 1 downregulated both unstimulated and NF-I-
induced a1(I) collagen promoter/reporter gene activities in
fibroblast cells ( 15 ). In contrast, elevated Sp 1 binding activities
were detected in models of experimentally induced liver fibro-
sis during periods of enhanced a 1 (I) gene transcription ( 16),
indicating the potential ofSp I to stimulate the a 1 (I) promoter
within the context of the intact gene.
Our in vitro analysis demonstrates that the GC-binding an-
tibiotic mithramycin binds to regulatory elements of the hu-
man a I(I) collagen promoter, which inhibits Spl and in-
creases NF-I binding to the NF-I/Spl switch elements. Recent
functional studies on the isolated NF-I/Sp switch elements
demonstrated that the ratio ofthe binding activities rather than
the absolute concentrations ofthe two transcription factors de-
termine a 1 (I) promoter activity ( 14). The present results sug-
gest a similar function of these elements in the intact aI (I)
gene. Competition with SpI and increased NF-I binding by
mithramycin leads to a substantial decrease of a 1 (I) gene tran-
scription and reduced levels of a I (I) mRNA in human fibro-
blasts. This implies further that Sp might be crucial for the
maintainance of the high transcriptional activity of the colla-
gen gene in human fibroblasts. These conclusions substantiate
a possible significant role of increased Sp binding activities
during the state ofenhanced collagen production in experimen-
tal fibrogenesis ( 16). Previous studies have demonstrated that
an enhanced activity of Sp can result from protein-protein
interactions of Sp 1 bound to the promoter with Sp I bound to
more distal sites (34). Additionally, high transcriptional activ-
ity of the SV40 enhancer required the binding of Spl to the
SV40 early promoter (35). Although a collagen-a I(I) en-
hancer element has not been unequivocally identified, en-
hancer-like activities were ascribed to the first intron of the
a I (I) gene ( 12), which contains functional Sp 1 binding sites
( 1 1, 36). Interestingly, synergistic interactions between colla-
gen-a 1 (I) intron and promoter sequences were reported re-
cently (37, 38 ) and could explain the different activities of Sp I
bound to the isolated promoter or to the promoter in the intact
gene. The potential of mithramycin to disrupt protein/protein
interactions of distal factors by interfering with the binding of
Sp 1 to GC-rich regulatory elements of the a 1 (I) promoter
could be a valuable tool in disclosing the mechanisms ofexperi-
mental fibrogenesis.
Mithramycin reduces fibronectin mRNA levels, which are
also upregulated in tissue fibrogenesis. This effect could only be
explained when further insight into the regulation of this gene
has been obtained. Similarly, the mechanisms how TGF-f
upregulates the a I(I) gene are not well understood but are
required to understand how mithramycin blocks this induc-
tion. Since TGF-3 is thought to be involved in the development
of many forms of tissue fibrosis, it will be interesting to exam-
ine in more detail how mithramycin interferes with its activity.




Our data further demonstrate that the basal transcription of
the collagenase gene is unchanged at nontoxic concentrations
of mithramycin. Therefore, it is possible to change the balance
between ECM deposition and degradation. This could have a
therapeutic impact in an already established fibrotic state.
Mithramycin interferes with the intracellular signaling
pathway through protein kinase C, resulting in an inhibition of
enhanced collagenase transcription by PMA. Since collagenase
activation is mediated by the formation of an APl transcrip-
tion factor complex (33), the observed inhibition of basal and
PMA-induced c-jun transcription by mithramycin could ex-
plain the effects. Mithramycin can inhibit the expression of
many genes perhaps by interfering with Sp I binding to regula-
tory elements ( 17-19). This might explain the narrow thera-
peutic range ofthis drug when used clinically (20). To increase
its therapeutic range mithramycin might be modified so that
the specificity of its DNA binding can be directed to crucial and
highly unique regulatory element in the target gene (39). An
interesting target for such a designed sequence specific DNA
binding drug might be the NF-I/Spl switch elements of the
collagen-a 1(I) gene.
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